Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment ...

The poster, titled Translational Insights from a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors, expands upon data presented at the recent European Society for Medical ...
BioWorld

Innocare Pharma divulges new CBLB inhibitors

Beijing Innocare Pharma Tech Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting

Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting ...
BioWorld

Simcere Pharmaceutical divulges new STAT6 degradation inducers

Simcere Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising E3 ubiquitin-protein ligands coupled to a signal transducer and activator of transcription 6 (STAT6) ...